NATIONAL ACADEMIES Sciences Engineering Medicine

Committee on Research Priorities for Preventing and Treating Alzheimer's Disease and Related Dementias

Public Workshop and Meeting #3
January 16–17, 2024

Speaker Biosketches

Laura Baker, PhD, is Professor of Internal Medicine (Geriatrics) and Public Health Sciences at Wake Forest University School of Medicine in Winston-Salem, North Carolina, and Associate Director of the NIA-supported Wake Forest Alzheimer's Disease Research Center. Dr. Baker is mPI of U.S. POINTER, the largest lifestyle clinical trial conducted to date with over 2000 participants enrolled. She has served as PI for three recently completed large national clinical studies focused on prevention of cognitive decline in older adults, including the Alzheimer's Disease Cooperative Study Phase III randomized trial of aerobic exercise in adults with MCI (EXERT), the Women's Health Initiative Sleep Hypoxia Effects on Resilience (WHISPER) study, and the COcoa Supplement and Multivitamins Outcomes Study of the Mind (COSMOS-Mind). She has led more than 55 clinical studies focused on normal and pathological aging, which include numerous treatment trials in adults with MCI or early AD. Dr. Baker is an invited member of several national workgroups convened by the NIH, the Alzheimer's Association, and the Centers for Disease Control to strategize around increasing underrepresented and underserved older adults in clinical trials, and helped to lead development of the NIH/NIA National Strategy for Recruitment and Participation in Alzheimer's and Related Dementias Clinical Research.

Lisa Barnes, PhD, is the Alla V. and Solomon Jesmer Professor of Gerontology and Geriatric Medicine and a cognitive neuropsychologist within the Rush Alzheimer's Disease Center at Rush University Medical Center. She is also the Associate Director of the Rush Alzheimer's Disease Research Center. She received her PhD from the University of Michigan in biopsychology and completed a post-doctoral fellowship in cognitive neuroscience at the University of California, Davis. She joined the faculty of Rush as an assistant professor in 1999. Dr. Barnes has received many NIH grants and has published over 300 manuscripts. She is internationally recognized for her contributions to minority aging and minority health. Her research interests include disparities in chronic diseases of aging, cognitive decline, and risk factors for Alzheimer's disease. She is the Principal Investigator of two longitudinal community-based studies of older African Americans, including the Minority Aging Research Study (MARS), which has been funded by NIA since 2004 and the African American Clinical Core which she has led since 2008. She advocates for recruitment of under-represented groups into clinical studies and has received many awards and fellowships from universities and organizations throughout the U.S.

Emelia Benjamin, MD, ScM, is a Boston University (BU) Chobanian and Avedisian School of Medicine, Professor of Medicine, and Robert Dawson Evans Distinguished Professor of

Medicine, and School of Public Health Professor of Epidemiology. She is a Framingham Study investigator and a Boston Medical Center (urban safety net hospital) cardiologist. She is an international leader in the epidemiology atrial fibrillation and has been continuously NIH funded since 1998 on grants related to atrial fibrillation, vascular function, inflammation, mobile health, and chronic pain. She is a Clarivate Highly Cited Researcher with an H-index of 205 and over 800 publications. Dr. Benjamin has Co-Chaired the NIH National Heart Lung and Blood Institutes' (NHLBI) Atrial Fibrillation Working Group, which advised the NHLBI's AF research agenda. She led the resultant atrial fibrillation white papers on screening (Circulation PMID 33493033), secondary prevention (JAHA PMID 34351783), and social determinants (JAMA Cardiol PMID 36478155). Dr. Benjamin is the inaugural Associate Provost for Faculty Development, BU Medical Campus. She has a fundamental commitment to post-graduate and faculty development and mentoring of individuals who are from underrepresented in health sciences and medicine, She has volunteered and had various leadership roles in the American Heart Association since the 1990s. A member of the Association of American Physician, she has won national awards for research, education, mentoring, and diversity, including the 2016 AHA Gold Heart Award, the 2022 AHA Distinguished Scientist Award, and the 2020 Alliance for Academic Internal Medicine Diversity and Inclusion Award.

David Bennett, MD, is director of the Rush Alzheimer's Disease Center and the Robert C. Borwell Professor of Neurological Sciences. The Rush Alzheimer's Disease Center is a large, free-standing multidisciplinary research and clinical center within Rush Medical College that studies a wide range of common chronic conditions of aging, including Alzheimer's disease, stroke, Parkinson's disease, other neurodegenerative diseases, sleep, neuro- and behavior economics, decision making and well-being. Studies range from community-based epidemiologic studies that incorporate genomics, imaging, and biomedical devices, to phase I-IV clinical trials. Dr. Bennett is internationally known for his research and is principal investigator of several studies funded by the National Institute on Aging, including the Religious Orders Study, the Rush Memory and Aging Project, and the Pathology, Alzheimer's and Related Dementias Study in Sao Paulo, Brazil. Dr. Bennett leads projects designed to identify novel therapeutics for common neurologic diseases. He also directs the Regional Alzheimer's Disease Assistance Center for Northern Illinois. He serves on numerous national and international advisory and editorial boards. He recently rotated off membership of the National Advisory Council on Aging for the National Institutes of Health. Dr. Bennett was the winner of the 2018 Potampkin Prize for research on dementia. He has more than 1150 peer-reviewed manuscript publications, with more than 180,000 citations and an h index = 199.

Niranjan Bose, PhD, MS, is the Managing Director for Health & Life Sciences at Gates Ventures, LLC, where he also serves as a Health & Life Sciences Advisor to Mr. Bill Gates. Gates Ventures' programmatic investments in the Alzheimer's field include the AD Diagnostics Accelerator, Dementia Discovery Fund (DDF), EQT Dementia Fund, AD Data Initiative and the European Platform for Neurodegenerative Diseases (EPND). Prior to joining Gates Ventures in 2014, he was the Chief of Staff to the President of the Global Health Program at the Bill & Melinda Gates Foundation. Dr. Bose holds a Ph.D. in Biochemistry from Dartmouth College's Geisel School of Medicine, an M.S. in Biological Sciences and a B.S. in Pharmaceutical Sciences from the Birla Institute of Technology and Science, in Pilani, India.

Rachel Buckley, PhD, is an Assistant Professor of Neurology at Massachusetts General Hospital and Harvard Medical School. After initially completing her PhD in Neuropsychology at the University of Melbourne, Australia, with the Australian Imaging Biomarker and Lifestyle Study of Aging, she then moved to Boston to train in PET neuroimaging and cognitive decline under Dr. Reisa Sperling at the Harvard Aging Brain Study. Her research interests lie in sex differences in risk for Alzheimer's disease, and she holds multiple NIH grants (K99/R00, DP2, R01) that seek to examine the role of menopause, sex hormones and the X chromosome to impact risk and resilience to AD in both men and women. Rachel is also the Chair of the Sex and Gender Differences in Alzheimer's disease Professional Interest Area for the Alzheimer's Association and sits on the editorial board for Neurology, as well as the Alzheimer's & Dementia sister journal, Diagnosis, Assessment & Disease Monitoring.

Goldie S. Byrd, PhD, joined the faculty at Atrium Health Wake Forest Baptist in 2018 as Professor of Social Sciences and Health Policy and Director of the Maya Angelou Center for Health Equity. She is the former Dean of the College of Arts and Sciences, Chair of the Department of Biology, Dean of the College of Arts and Sciences, and Nathan F. Simms Endowed Distinguished Professor of Biology at A&T. Dr. Byrd's interest is on the Genetics of Alzheimer's disease in African Americans. Her research focuses on the inclusion of special populations in Alzheimer's research and clinical trials. At NC A&T, Dr. Byrd founded the Center for Outreach in Alzheimer's Aging and Community Health (COAACH) to complement her genetics of Alzheimer's work by increasing awareness of the disease in minoritized communities, improving access to care and increasing opportunities for learning and research participation. At Wake Forest, Dr. Byrd directs the Integrating Special Populations Program for the CTSI and is co-director of the Outreach Recruitment and Engagement core of the Alzheimer's Disease Research Center. Dr. Byrd has received numerous awards for her leadership, teaching, research, student mentoring and service, including the Presidential Award for Excellence in Science Mathematics and Engineering Mentoring (PAESMEM). This award was received from President Barak Obama, at a White House ceremony. She was also recently honored as a Most Influential Person of African Descent in Health Equity, as part of a United Nations sponsorship.

Maria Carrillo, PhD, is the Chief Science Officer for the Alzheimer's Association, where she sets the strategic vision for the global research program of the Alzheimer's Association. Under her leadership, the Association is the world's largest nonprofit funder of Alzheimer's research and an internationally recognized pioneer in convening the dementia science community to accelerate the field. Dr. Carrillo oversees the implementation of the Association's growing portfolio of research initiatives, including the Alzheimer's Association International Conference® (AAIC®), the world's largest and most influential dementia science meeting, and the Research Roundtable, which enables international scientific, industry and government leaders to work together to overcome shared obstacles in Alzheimer's science and drug development. Additionally, Dr. Carrillo is a co-principal investigator for the Alzheimer's Network for Treatment and Diagnostics (ALZ NET), which is designed to track the long-term clinical response and safety outcomes of enrolled patients being treated with novel FDA-approved Alzheimer's therapies. Under Dr. Carrillo's direction, the Association's leadership in Alzheimer's research continues to thrive through its International Research Grant Program, which is currently investing $320 million in more than 1,000 active best-of-field projects in 54 countries, spanning six continents.

Diane Cook, PhD, MS, is a Regents Professor and a Huie-Rogers Chair Professor in the School of Electrical Engineering and Computer Science at Washington State University. Dr. Cook received her B.S. from Wheaton College in 1985, and her M.S. and Ph.D. from the University of Illinois in 1987 and 1990, respectively. Dr. Cook's research interests include artificial intelligence, machine learning, data mining, robotics, smart environments, and parallel algorithms for artificial intelligence. She is one of the directors of the AI Laboratory and heads the CASAS smart home project. She also co-directs the NIH Training Program in Gerontechnology.

Maria Corrada-Bravo, ScD, ScM, is a Professor in the Department of Neurology and the Department of Epidemiology and Biostatistics at the University of California, Irvine. She is also leader of the 90+ Core at the UCI Alzheimer's Disease Research Center. She received her bachelor's degree at the University of Puerto Rico, and completed a masters in Biostatistics and a doctorate in Psychiatric Epidemiology at the Johns Hopkins School of Public Health in Baltimore, MD. Early in her career, she worked on projects involving the Baltimore Longitudinal Study of Aging, including some of the earliest prospective studies of estrogen replacement therapy, non-steroidal anti-inflammatory drugs, and folate as protective factors for Alzheimer's disease. She moved to UCI to help establish The 90+ Study, for which she is a multiple principal investigator. The 90+ Study is a longitudinal epidemiological study of aging and dementia of more than 2,000 well-characterized people aged 90 years and older. Some of her most important contributions have been estimating prevalence and incidence of dementia, as well as investigating the role of multiple pathologies to dementia in this age group. In addition, Dr. Corrada is multiple principal investigator for Life After 90 a recently established life-course study of cognitive impairment and dementia in a racially and ethnically diverse cohort of over 1,000 people aged 90 and older in Northern California. Dr. Corrada's research interests include population-based longitudinal studies, the epidemiology of dementia, and through imaging and autopsy studies, identifying factors that correlate with the presence of brain pathologies. Much of her work has been dedicated to understanding the cognitive and physical health of the oldest-old, a rapidly growing, but understudied population.

Jeffrey Cummings, MD, ScD, joined the UNLV School of Integrated Health Sciences in 2019 as research professor within the department of brain health. Dr. Cummings is the Joy Chambers-Grundy Professor of Brain Science, an endowed professorship. He is the Director of the Chambers-Grundy Center for Transformative Neuroscience, a center devoted to using the tools of neuroscience and neurologic drug development to transform people's lives. Prior to UNLV, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo for Brain Health in Las Vegas, and as director of the Mary S. Easton Center for Alzheimer's Disease Research, and director of the Deane F. Johnson Center for Neurotherapeutics, both at UCLA. A world-renowned Alzheimer's researcher and leader of clinical trials, Dr. Cummings has been recognized for his scientific and leadership contributions with the American Geriatrics Society's Henderson Award (2006), the national Alzheimer's Association's Ronald and Nancy Reagan Research Award (2008), and the American Association of Geriatric Psychiatry's Distinguished Scientist Award (2010). Dr. Cummings' interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. Dr. Cummings has

published nearly 800 articles and 44 books devoted to neuroscience, Alzheimer's disease, and clinical trials.

David Cutler, PhD, has developed an impressive record of achievement in both academia and the public sector. He served as Assistant Professor of Economics from 1991 to 1995, was named John L. Loeb Associate Professor of Social Sciences in 1995, and received tenure in 1997. He is currently the Otto Eckstein Professor of Applied Economics in the Department of Economics and was named Harvard College Professor in 2014 until 2019. Professor Cutler holds secondary appointments at the Kennedy School of Government and the School of Public Health. Honored for his scholarly work and singled out for outstanding mentorship of graduate students, Professor Cutler's work in health economics and public economics has earned him significant academic and public acclaim. Professor Cutler served on the Council of Economic Advisers and the National Economic Council during the Clinton Administration and has advised the Presidential campaigns of Bill Bradley, John Kerry, and Barack Obama as well as being Senior Health Care Advisor for the Obama Presidential Campaign. Among other affiliations, Professor Cutler has held positions with the National Institutes of Health and the National Academy of Sciences. Currently, Professor Cutler is a Research Associate at the National Bureau of Economic Research and a member of the National Academy of Medicine. Professor Cutler is author of three books and many published papers on the topics of health care and other public policy topics. Professor Cutler's ideas were the subject of a feature article in the New York Times Magazine, The Quality Cure, by Roger Lowenstein.

Krik Erickson, PhD, is Director of Translational Neuroscience and Mardian J. Blair Endowed Chair of Neuroscience at the AdventHealth Research Institute, Neuroscience Institute. Dr. Erickson is also a Professor of Psychology and Neuroscience at the University of Pittsburgh. Dr. Erickson received his Ph.D. at the University of Illinois at Urbana-Champaign and was a post-doctoral scholar at the Beckman Institute for Advanced Science and Engineering. Dr. Erickson's vast research program focuses on the effects of physical activity on brain health across the lifespan. This research has resulted in > 300 published articles and 15 book chapters. Dr. Erickson's research has been funded by numerous awards and grants from NIH, the Alzheimer's Association, and other organizations. He has been awarded a large multi-site Phase III clinical trial examining the impact of exercise on cognitive function in cognitively normal older adults as well as a grant to follow-up on all participants. His research resulted in the prestigious Chancellor's Distinguished Research Award from the University of Pittsburgh. He was named a Fellow of the Academy of Behavioral Medicine Research in 2016, and a Distinguished Scientist Award by Murdoch University in 2018. He has held Visiting Professor appointments at Murdoch University in Australia, the University of South Australia, the University of Granada, Spain, and the Max Planck Institute in Berlin, Germany.

Laura Esserman, MD, MBA, is a surgeon and breast cancer oncology specialist practicing at the UCSF Breast Care Center where she has also held the position of Director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center's multidisciplinary programs. The program is comprised of 69 faculty members who represent 16 academic specialties and is internationally recognized and well-established with major initiatives in epidemiology, genetics, biology, therapeutics, and clinical cancer care. She is a professor of Surgery & Radiology at UCSF and faculty at the UCSF Helen Diller Family

Comprehensive Cancer Center where she founded the program in Translational Informatics. As part of this program, her research has focused on bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.

Daniel Gibbs, MD, PhD, is a retired neurologist and former neurologist at Oregon Health and Science University. Dr. Gibbs retired in 2013 due to Mild Cognitive Impairment (MCI) due to Alzheimer's Disease. Since his diagnosis, Dr. Gibbs has been writing about his own brain and disease book, A Tattoo on my Brain: A Neurologist's Personal Battle Against Alzheimer's Disease, in several journal papers and a blog (tatooonmybrain.com).

Jürgen Götz, PhD, is the Lesleigh Green - Bill and Nancy Green Endowed Chair in Dementia Research and inaugural Director of the Clem Jones Centre for Ageing Dementia Research (University of Queensland). Professor Götz studied biochemistry in Switzerland and earned his PhD in immunology with Nobel Laureate Köhler in Germany. After postdoctoral work at UCSF and at Novartis, he became a group leader in Zürich, before moving to the University of Sydney in 2005, and then to the University of Brisbane (Queensland Brain Institute) in 2012. A major focus of his laboratory is to gain insight into how tau and amyloid both separately and synergistically contribute to Alzheimer's disease. In recent years, the laboratory has started to develop therapeutic ultrasound into a treatment modality for Alzheimer's disease and other brain diseases, both by transiently opening the blood-brain barrier and as a neuromodulatory tool. Professor Götz has published more than 230 papers in leading journals including Cell, Science and Neuron, and has authored many authoritative reviews in the Nature Reviews journal family.

Agustín Ibáñez, PhD, is the Director of the Latin American Brain Health Institute (BrainLat) and a full professor at the Universidad Adolfo Ibanez. He also holds positions as a Senior Atlantic Fellow at GBHI-UCSF, Associate Research Professor at GBHI-Trinity College Dublin, and Group Leader of the Predictive Brain Health Modelling Group at Trinity College Dublin. He has a distinguished track record in the field of brain health and diversity, with over 350 publications and significant citations (citations >16500; h-index >74; i10-index >290: Google Scholar: https://bit.ly/3nRm5m3), including more than 130 publications in the last five years in top-tier journals such as Nature Medicine, World Psychiatry, Lancet Neurology, and others. His research explores disparity and diversity in brain health, focusing on conditions like frontotemporal dementia (FTD), Alzheimer's disease (AD), and other neurodegenerative diseases, examining social determinants of health, cognition, memory, and genetics. He has developed computational frameworks for neurodegeneration studies and a multimodal approach to AD and bvFTD. Dr. Ibanez is committed to advancing a translational neuroscientific approach to dementia in Latin America and across diverse global settings. He has been instrumental in establishing frameworks to engage scientists in translational science, organizing educational programs for the medical community, and developing an active, multi-institutional agenda to elevate public awareness of neuroscience in the region. He co-coordinates the Latin American and Caribbean Consortium on Dementia (LAC-CD) with Dr. Parra. He is the founder and co-director of the Multi-partner Consortium to Expand Dementia Research in Latin America (ReDLat), supported by various institutions, including NIH/NIA and Alzheimer's Association. ReDLat has developed a comprehensive clinical and research platform for dementia in the region. Ibanez's work has received extensive media coverage, including in the BBC, Nature,

Nature News, Discovery Channel, Popular Science, Daily Mail, Newsweek, Le Monde, and Oxford University Press.

Michael Irizarry, MD, MPH, joined Eisai in September 2018 as Vice President of Clinical Research, Epilepsy/Sleep, in which he led the clinical development of Eisai's Epilepsy and Sleep/Wake programs, including regulatory submissions for compounds that received regulatory approvals to treat epilepsy and insomnia. He was named Vice President of Clinical Research for the Neurology Business Group in May 2019, and soon promoted to his current dual role in April 2020. Prior to joining Eisai, Dr. Irizarry served as Vice President, Early Clinical Development, Neurosciences at Eli Lilly, responsible for the Phase 1 and 2 neurosciences portfolio. His focus was on neurodegeneration advancing molecules from candidate selection to investigational new drug applications, up through proof of concept studies. Before joining Eli Lilly, he was Acting Vice President, World-Wide Epidemiology at GlaxoSmithKline, where his team of more than 60 epidemiologists and database analysts supported clinical trial planning; safety and effectiveness studies; and oversight and application of in-house claim databases and electronic health records. Dr. Irizarry earned undergraduate and medical degrees from Georgetown University, and a Master of Public Health (M.P.H.) degree from the Harvard School of Public Health. He completed his neurology residency and Memory Disorders Fellowship at Massachusetts General Hospital and continued as a member of the Harvard Medical School faculty at the Massachusetts Alzheimer's Disease Research Center. His research has encompassed molecular mechanisms, clinical-pathological correlations, animal models, biomarkers, and epidemiology of neurodegenerative diseases, especially Alzheimer's disease.

Jeffrey Kaye, MD, is the Layton professor of neurology and biomedical engineering and the director of the Layton Aging and Alzheimer's Disease Center, as well as director of the Oregon Center for Aging and Technology (ORCATECH). Dr. Kaye received his medical degree from New York Medical College and trained in neurology at Boston University. He completed fellowships in Movement Disorders at Boston University and in brain aging at the National Institute on Aging. He moved to Oregon in 1989 to develop the Layton Aging and Alzheimer's Disease Center. Dr. Kaye has received the Charles Dolan Hatfield Research Award for his work. He is listed in Best Doctors in America. He serves on many national and international panels and review boards in the field of geriatrics and neurology. He is an author on over 400 scientific publications and holds several major grant awards from federal agencies, national foundations, and industrial sponsors. Dr. Kaye serves as a member of the OHSU Healthy Aging Alliance Executive Committee.

Zaven Khachaturian, PhD, is the President of Prevent Alzheimer's Disease 2020 [PAS2020] Inc. www.pad2020.org. He is the Founding Editor-in-Chief [Emeritus] of Alzheimer's & Dementia. His career spans several high-level positions requiring strategic decisions regarding public policies on national R&D programs. He is generally acknowledged as the 'Founder - Chief Architect' of the extramural research programs on Neurobiology of Aging and Alzheimer supported by the National Institution on Aging (NIA) / National Institutes of Health [NIH]. During his tenure at NIH, he served the dual role of Director, Office of Alzheimer's Disease, responsible for coordinating all Alzheimer's disease related activities NIH-wide; as well as the Associate Director for the Neuroscience and Neuropsychology of Aging Program (NNA) at the NIA/NIH. In these positions he was responsible for planning, developing, and administering

major national programs of research on Alzheimer's disease and brain aging. He was instrumental in making Alzheimer's disease a top priority of the US Government and the subsequent unlocking of federal funding for research. Throughout his career he has serves as mentor to countless investigators. He had a direct hand in launching the scientific-academic calling careers of many prominent and successful researchers in the field of dementia-Alzheimer syndrome in the U.S. as well as other counties.

Amy Kind, MD, PhD, is a world-renowned expert in the field of disparities-focused exposome science, social determinants, and Alzheimer's disease. Her field-changing research launched new NIH and Congressional initiatives on exposome study, is heralded as a model for open data, and provides the foundation for Medicare's new 2023 federal equity-payment models. Kind's work fundamentally changes the way we conceptualize health disparities, by refocusing policy, research and clinical delivery from the single individual to the social exposome (the individual's life-course context). Kind developed and extensively studied the geo-precise Area Deprivation Index (ADI), the now dominant metric of social exposome study. Kind's ADI serves as the foundation for Medicare's ground-breaking 2023 federal equity health payment policy (ACO-REACH). She makes the ADI available to all through the Neighborhood Atlas, a free first-of-its-kind online data democratization tool that provides ADI access and visualizations for every neighborhood in the US. Her Atlas data are accessed over one-half million times, employed by thousands of research teams, and applied across NIH core research resources, state and federal policy, health system operations, and industry product development. Her work directly led to 2022 Congressional appropriation for exposome-brain health research, is heralded by NIH as an open science exemplar, published in top journals including The New England Journal of Medicine, and garners many national awards. Kind has been continuously NIH funded, with a current NIH research portfolio exceeding $40 million. Her portfolio includes developing and leading the NIH-funded $28 million "Neighborhoods Study", a first-in-field 23-site national consortium on life-course exposome and imaging, fluid, and neuropathological markers of Alzheimer's disease. Dr. Kind currently serves as the Associate Dean for Social Health Sciences and Programs at the University of Wisconsin (UW) School of Medicine and Public Health. As Associate Dean, Dr. Kind serves as Executive Director of the $400 million Wisconsin Partnership Program grant-making endowment, Director of the UW Center for Health Disparities Research, and provides oversight to the Milwaukee-based Center for Community Engagement and Health Partnerships. In addition, Dr. Kind is a Professor of Medicine and serves as Leader of the Care Research Core of the Wisconsin Alzheimer's Disease Research Center.

Ian Kremer, JD, has worked on federal, state, and local dementia for over 27 years. Since 2012, Kremer has served as Executive Director of the LEAD Coalition (Leaders Engaged on Alzheimer's Disease: http://www.leadcoalition.org), the uniting voice of over 260 member and allied organizations, along with hundreds of university-based researchers. The LEAD Coalition works collaboratively through federal public policy to improve quality of life for all people facing dementia while advancing the social and biomedical sciences to prevent, treat, and ultimately cure all forms of dementia. Currently, Kremer serves on the CMS Medicare Evidence Development & Coverage Advisory Committee, the Public Policy & Aging Report editorial board, and on steering and advisory committees for a half dozen NIA and CDC-supported projects, the Alzheimer's Disease Patient and Caregiver Engagement initiative, the Digital Medicine Society's ADRD Core Digital Clinical Measures project, the Dementia Friendly

America initiative, the Alzheimer's Association Dementia Care Navigation Roundtable, and the Davos Alzheimer's Collaborative Champions Cabinet. Previously, Kremer served on the steering committees for the NIH's 2017 and 2020 National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers, the CDC-Alzheimer's Association Healthy Brain Initiative's Leadership Committee developing the 2018-2023 and the 2023-2027 Public Health Roadmaps, and the FDA Stakeholders Working Groups for PDUFA VI and PDUFA VII. Kremer holds degrees from Washington University in Saint Louis and the University of Michigan School of Law.

Bruce Lamb, PhD, is the Roberts Family Chair in Alzheimer's Disease Research and Executive Director of the Stark Neurosciences Research Institute at the Indiana University School of Medicine. Dr. Lamb received his bachelor's degree from Swarthmore College and his PhD from the University of Pennsylvania, prior to a post-doctoral fellowship at Johns Hopkins University. In 1996, Dr. Lamb was recruited to Case Western Reserve University, where he rose from Assistant to Associate Professor and finally moved to the Cleveland Clinic in 2005. At the Cleveland Clinic, Dr. Lamb was promoted from Associate Professor to Full Professor in 2011. Dr. Lamb was recruited to become the Executive Director of the Stark Neuroscience Research Institute in January of 2016 and is Co-Director of the Indiana University Health Neuroscience Institute since 2020. Dr. Lamb's laboratory works on the basic science of Alzheimer's disease, with a focus on 1) genetic modifiers identified from both mouse and human studies, 2) microglia and neuronal-microglial communication in the development and progression of AD pathologies; and 3) traumatic brain injury as an environmental modifier for the development of AD pathologies. Dr. Lamb is Director of the Indiana University/Jackson Laboratory/University of Pittsburgh Model Organism Development and Evaluation for Late-onset Alzheimer's Disease (MODEL-AD) Center and Co-Director of the IUSM/Purdue Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT-AD) Center, both funded by the NIH. In addition, Dr. Lamb is actively involved in advocacy for increased research funding for the disease. Dr. Lamb was the Leader of the Alzheimer's Breakthrough Ride in 2010, a cross-country bicycle event supported by the Alzheimer's Association that featured researchers cycling from California to Capitol Hill to draw attention to the cause. Dr. Lamb has received numerous awards and honors including the Jennifer B. Langston Award from the Cleveland Chapter of the Alzheimer's Association and the National Civic Award and Zaven Khachaturian Lifetime Achievement Award from the National Alzheimer's Association, is a Fellow in the American Association for the Advancement of Science, and Chair of the Medical and Scientific Advisory Group and member of the Board of Directors of the National Alzheimer's Association.

Virginia Lee, PhD, is The John H. Ware 3rd Endowed Professor in Alzheimer’s Research at the University of Pennsylvania Perelman School of Medicine. She is also the Director of the Center for Neurodegenerative Disease Research and Co-Director of the Marian S. Ware Center for Alzheimer’s Drug Discovery Program. Dr. Lee’s research focuses on disease proteins that form pathological inclusions in hereditary and sporadic Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS) and related neurodegenerative disorders of aging. Her work demonstrated that tau, alpha-synuclein and TDP-43 proteins form unique brain aggregates in neurodegenerative diseases and provided critical evidence that aggregation of brain proteins is a common mechanistic theme in diverse neurodegenerative diseases including AD, PD, FTLD, ALS and related disorders. Significantly,

Dr. Lee's studies implicated the abnormal aggregation of tau, alpha-synuclein and TDP-43 in mechanisms that compromise neuronal viability. Most importantly, this research has opened up new avenues of research to identify targets for drug discovery to develop better treatments for these disorders. Dr. Lee received her MSc in Biochemistry from the University of London, PhD in Biochemistry from the University of California San Francisco, and MBA from Wharton School; University of Pennsylvania. She attended post graduate training at the University of Utrecht and Harvard Medical School.

Gill Livingston, MD, is currently a professor of Psychiatry of Older People at the University College London. is a clinical academic, working with people with suspected or confirmed dementia and their families. Her work is interdisciplinary and considers mechanisms through epidemiological and biopsychosocial enquiry, using them to co-design evidence-based interventions and test them. She led the Lancet Standing Commission on Dementia Prevention, Intervention and Care, 2017 and 2020. These produced new research and meta-analyses of life-course risk and an overview of current knowledge on interventions. The findings have substantial implications in preventing and delaying a significant proportion of dementia. They have resulted in changes in UK and US policy which aim to reduce dementia risk. She also researches interventions to improve the lives of people with dementia and their families and staff caring for them and particularly consider underserved and minority communities. START for family carers has long-lasting effects on depression and anxiety symptoms, increases quality of life, is cost-effective and might save money.

Tim MacLeod, PhD, is the Director of the Systems Preparedness workstream of the Davos Alzheimer's Collaborative (DAC). The mission of the systems preparedness program is to facilitate the implementation of national, regional, and global commitments to provide access to future innovations in treatment, diagnosis, and care. Drawing on his background in implementation science and innovation consulting, Tim guides the development, execution, and dissemination of multi-site, real-world implementation studies that generate evidence about the facilitators and barriers to adopting and scaling novel technology in the ADRD space. Before joining DAC, Tim led the award-winning human-centered design studio Bridgeable as Managing Director, where he worked with Fortune 500 companies in the financial service and health spaces on significant innovation initiatives. During his tenure at Bridgeable, Tim helped to significantly grow the practice by focusing on emerging health challenges, including digital health, global health systems preparedness in the Alzheimer's space, and health systems preparedness in the US for the COVID-19 vaccine rollout. Tim holds a Ph.D. in community psychology and has published widely on health innovation and implementation science. Tim's research with the Mental Health Commission of Canada's At Home/Chez Soi team scaled the Housing First model from 5 pilot sites to over 20 cities nationally through multi-level policy change.

Mark Mapstone, PhD, MA, is a translational neuroscientist and professor at the University of California, Irvine School of Medicine. Dr. Mapstone is also the Vice Chair for Research in Neurology and Faculty at the Institute for Memory Impairment and Neurological Disorders. His goal is to translate discoveries about the aging brain into practical and implementable approaches for successful cognitive aging at the individual level. His current work is focused on early detection of age-related neurological disease especially Alzheimer's disease and Parkinson's disease using careful cognitive phenotyping and biomarkers obtained from blood. He is using this information to develop screening tools that can be used to enrich clinical trials with

appropriate subjects for disease modifying interventions. He hopes to develop reliable biomarkers for clinical use. Dr. Mapstone received his MA in Psychology from Boston University and his PhD in Clinical Psychology from Northwestern University.

Dawn Mechanic- Hamilton, PhD, ABPP/CN, joined the Penn Memory Center in 2012. She is an assistant professor in the Department of Neurology and director of Cognitive Fitness Programs and Neuropsychological Services at the Penn Memory Center. She earned her Ph.D. in clinical psychology with a concentration in neuropsychology from Drexel University. She completed her internship at Brown University and postdoctoral fellowship in clinical neuropsychology at the University of Pennsylvania. Dr. Mechanic-Hamilton's research and clinical work focuses on neuropsychological assessment and cognitive and behavioral intervention in patients with cognitive impairment. She is involved in ongoing clinical trials at the Penn Memory Center, is a collaborator on multidisciplinary research projects, and supervises trainees from clinical psychology doctoral programs in the Philadelphia region.

Gary Miller, PhD, is a Professor of Environmental Health Sciences at Columbia University. He is a leader in the exposome field, which strives to provide a systematic and comprehensive analysis of the non-genetic contributors to health and disease. He was the founding director of the HERCULES Exposome Research Center at Emory University, the first exposome-based research center in the U.S. He authored the first book on the topic, The Exposome: A Primer published by Elsevier. His research focuses on environmental drivers of neurodegeneration. His laboratory uses a variety of methods including transgenic mouse production, immunohistochemistry, neurotransmitter transport assays, high-resolution metabolomics, electrochemistry, and behavioral assays. His work is conducted in several experimental models from cultured neurons and C. elegans to mice and human studies.

Ralph Nixon, MD, PhD, is a Professor in the Department of Psychiatry and the Department of Cell Biology at New York University Grossman School of Medicine. Dr Nixon is a Temple Foundation and Zenith Fellows awardee, has been a pioneer in the area of understanding how proteins are made, shuttled through cells and degraded. Dr. Nixon has pioneered the discovery of new biological pathways that may explain how autophagy and the endosomal/lysosomal pathway go awry and cause proteins to accumulate in and around nerve cells. It is this accumulation that is thought to cause nerve cells to die in Alzheimer's and other neurodegenerative diseases. Since his 2003 Zenith Award, Dr. Nixon has been awarded nearly $15 million in National Institutes of Health (NIH) funding related to Alzheimer's and other dementias research. Dr. Nixon and colleagues have made several key discoveries related to the role of autophagy in Alzheimer's. Dr. Nixon has found that proteins associated with Alzheimer's disease, including presenilin-1 (PS-1) and amyloid precursor protein (APP), may affect the function of endosomal/lysosomal pathway and potentially contribute to the accumulation of toxic beta-amyloid in the brain. In addition, his research team has been instrumental in uncovering the specific proteins that cause endosome dysfunction and trigger a cascade of events that lead to nerve cells loss. Because endosome dysfunction occurs very early in the disease process, therapies that target this process may help slow or halt the disease process before irreversible damage occurs.

Sid O'Bryant, PhD, is the principal investigator of the Health & Aging Brain Study – Health Disparities (HABS-HD), which is the most comprehensive study of Alzheimer's disease among the three largest racial/ethnic groups in the U.S. ever conducted – African Americans, Hispanics, non-Hispanic whites. The goal of the HABS-HD program is to understand the life course factors, including biological, sociocultural, environmental, and behavioral, that impact risk for Alzheimer's disease in late life. This work will ultimately lead to population-specific precision medicine approaches to treating and preventing Alzheimer's disease (i.e., "treating your Alzheimer's disease"). In addition to being a global leader in health disparities in cognitive aging, Dr. O'Bryant is a global expert in the use of blood-based biomarkers for the generation of a precision medicine approach to novel diagnostic and therapeutic strategies for Alzheimer's disease, Parkinson's disease, Dementia with Lewy Bodies and Alzheimer's disease among adults with Down Syndrome.

Yannis Paschalidis, PhD, is a Distinguished Professor of Electrical and Computer Engineering, Systems Engineering, and Biomedical Engineering, and Founding Professor of Computing & Data Sciences at Boston University. He is the Director of the Hariri Institute for Computing and Computational Science & Engineering -- BU's federation and convergence accelerator of all University centers and initiatives in this area of research. He obtained a Diploma (1991) from the National Technical University of Athens, Greece, and an M.S. (1993) and a Ph.D. (1996) from the Massachusetts Institute of Technology (MIT), all in Electrical Engineering and Computer Science. His current research interests lie in the fields of optimization, control, stochastic systems, robust learning, computational medicine, and computational biology. He has published a monograph and more than 270 refereed papers in these topics, and he has been the primary advisor to 32 Ph.D. theses. His work has been recognized with a CAREER award from the National Science Foundation, several best paper awards, and an IBM/IEEE Smarter Planet Challenge Award. His work on health informatics won an IEEE Computer Society Crowd Sourcing Prize and a best paper award by the International Medical Informatics Associations (IMIA). He was an invited participant at the 2002 Frontiers of Engineering Symposium organized by the National Academy of Engineering, and at the 2014 National Academies Keck Futures Initiative (NAFKI) Conference. He is a Fellow of both IEEE and IFAC (International Federation of Automatic Control) and was the founding Editor-in-Chief of the IEEE Transactions on Control of Network Systems from 2013 until 2019.

Russ Paulsen, MA, joined UsAgainstAlzheimer's as chief operating officer in 2019. Revenue and staff have steadily increased, enabling the organization to take on projects like a consumer-focused web platform that has brough 500,000 people information tailored to their specific Alzheimer's journey. UsAgainstAlzheimer's received its first-ever funding from the Centers for Disease Control and Prevention for outreach in Black and Latino communities; assembled a 100-organization coalition to set a national Alzheimer's risk-reduction goal; and published rigorous research on what matters to people living with Alzheimer's and those who love them. Prior to joining UsAgainstAlzheimer's, Russ was a senior executive at the American Red Cross. Among other accomplishments, he led the team there who created a campaign to reduce deaths from home fires; it has saved more than 2000 lives since its launch and made 1.1 million high-risk homes safer through smoke alarms and fire escape plans. More than 1.7 million kids have learned about fire safety through classroom presentations and an award-winning videogame.

Margaret Pericak-Vance, PhD, is Director of the John P. Hussman Institute for Human Genomics and Executive Vice Chair of the Dr. John T. Macdonald Foundation Department of Human Genetics at the University of Miami Miller School of Medicine. Board certified by the American Board of Medical Specialties in Medical Genetics, she is a founding fellow of the American College of Medical Genetics and an elected member of the National Academy of Medicine. She has produced more than 750 scholarly publications, which have been cited at least 115,428 times in the scientific literature and earned an h-index of 142. Dr. Pericak-Vance's laboratory made the seminal discovery of the first association of a common genetic risk variant, the apolipoprotein e4 allele (APOE-4) for late-onset Alzheimer disease, followed closely by the identification of the APOE-2 allele as a genetic protective variant for Alzheimer disease. Many of Dr. Pericak-Vance's efforts are directed towards addressing health disparities in genomics research. She directs several related genetic research projects, one on Alzheimer disease in African Americans and a second on admixed Caribbean Hispanic and Amerindian populations. In 1997, Newsweek Magazine named her to "The Century Club," as among the "100 people to watch" as we move to the next millennium Dr. Pericak-Vance is the recipient of numerous awards, including the international "Louis D" Scientific Prize from the Institut de France's Academie des Sciences for her Alzheimer disease research, the Bengt Winblad Lifetime Achievement Award from the Alzheimer's Association and the Snow and Ming Tsuang Lifetime Achievement Award from the International Society of Psychiatric Genetics (ISPG) for her lifelong contribution to psychiatric disease research.

Rema Raman, PhD, is a Professor of Neurology at Keck School of Medicine of USC and the Director of Biostatistics at the USC Alzheimer's Therapeutic Research Institute (ATRI). She is the lead of the Biostatistics Unit and the co-lead of the Recruitment Unit for the Alzheimer's Clinical Trials Consortium (ACTC). Dr. Raman has focused her academic career in the design, conduct and analysis of clinical trials in neurology. She has extensive experience as a collaborative biostatistician and clinical trialist, serving in the leadership team of several highly integrated and interdisciplinary research programs conducting clinical research in Alzheimer's disease, acute stroke, post-traumatic stress disorder, and traumatic brain injury. Her primary statistical research interests are in correlated and missing data issues, design and analysis of efficient clinical trials and cohort studies, centralized and adaptive statistical monitoring approaches, and effective safety monitoring. Dr. Raman is deeply committed to the effective teaching of and clinical trial methodology to medical students, graduate students, clinical fellows, and other clinical researchers. She has taught clinical trials to graduate students and medical residents/fellows and Biostatistics to basic science and public health graduate students as well as medical students. She has trained physicians on biostatistics and clinical research methodology and provided the statistical mentorship to many research projects. She is co-director of the Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD), a course that aims to educate and promote diversity among research professionals and future principal investigators in the field of Alzheimer's Disease and Related Disorders research, and the co-Chair of the ACTC Inclusion, Diversity and Education in Alzheimer's disease Clinical Trials (IDEA-CT) committee.

Meg Smith, JD, was named Chief Executive Officer of Cure Alzheimer's Fund effective October 1st, 2023, after eight years of successfully building and managing the research program and serving in increasing levels of leadership, most recently as Executive Vice President,

Research Management. Meg joined Cure Alzheimer's Fund as Senior Advisor, Strategy and Special Projects, in 2015 and was promoted to Executive Vice President, Research Management, in 2021. Through Meg's stewardship of our research funding program, Cure Alzheimer's Fund has made $138 million in research grants—nearly 80% of total distributions since our founding in 2004. This funding has resulted in enormous progress and remarkable discoveries from our scientists. Meg's leadership and guidance has also helped to inspire an impressive 7.5X in follow-on funding from the National Institutes of Health, multiplying our impact with the progress of Alzheimer's disease research and our mission. All of this is a direct result of the standard of excellence that Meg has brought to the CureAlz research funding process. Previously, Meg was with McKinsey & Company after clerking for the Massachusetts Supreme Judicial Court and serving as a Fellow at the Berkman (now Berkman Klein) Center for Internet & Society at Harvard Law School. Meg holds a juris doctor degree from Harvard Law School and a bachelor of science degree from Duke University.

Bart de Strooper, MD, PhD, is the founding director of the UK Dementia Research Institute. He has brought together the top research in the UK to tackle this major health concern. His vision is to "fill the knowledge gap", identifying novel mechanisms of neurodegeneration and translating them to drug targets and biomarkers. His own work is focused on the cellular mechanisms of early Alzheimer's disease. Bart is a medical doctor (1985) and a master in biomedical sciences (1987). He obtained a PhD from the KULeuven (Belgium) and performed postdoc studies in the laboratorium of prof. Carlos Dotti (EMBL, Germany). He is currently a professor at the University of Leuven and at University College London. Bart's groundbreaking research was rewarded with several prestigious prizes, including most recently the 2018 Brain Prize together with John Hardy, Christian Haass and Michel Goedert. In 2019, he was awarded a prestigious ERC Advanced Grant to develop mouse-human chimeric mouse models. In 2022 he was one of the ten international researchers elected to the US National Academy of Medicine. Bart is the founder of two spin-off companies and inventor on 17 patents.

Ameer Taha, PhD, MS; is a professor of Food Science and Technology at The University of California, Davis. Dr. Taha received his PhD in Pharmacology and Toxicology and MS in Nutritional Sciences from the University of Toronto. His research focuses on Understanding the mechanisms of oxidized linoleic acid metabolite formation and impact on health will aid in devising strategies to minimize human exposure and will help establish dietary safety limits.

Charlotte Teunissen, PhD, MS, is driven to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis, and monitoring treatment responses. Studies of her research group span the entire spectrum of biomarker development, starting with biomarker identification, often by –omics methods, followed by biomarker assay development and analytical validation, and lastly, extensive clinical validation and implementation of novel biomarkers in clinical practice. She has extensive expertise with assay development on state of the art technologies, such as mass spectrometry and antibody-based arrays for biomarker discovery, ultrasensitive immunoassays, and in in implementation of vitro diagnostic technologies for clinical routine lab analysis. She is responsible for the large well-characterised biobank of the Amsterdam Dementia cohort, containing >10000 paired CSF and serum samples of individuals visiting the memory clinical of the Alzheimer Center Amsterdam (a.o. controls, patients with Alzheimer, Frontotemporal, Lewy Bodies). To ensure the quality of the biosamples, the group studies pre-analytical effects, which are key to

implementation. Charlotte is leading several collaborative international biomarker networks, such as the Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization and Blood Based Biomarkers and the Body fluid Biomarkers PIA, and the recently founded Coral proteomics consortium. She is the coordinator of the Marie Curie MIRIADE project, aiming to train 15 novel researchers into innovative strategies to develop dementia biomarkers (10 academic centers + 10 non-academic centers), and the JPND bPRIDE project, that aims to develop targeted blood-based biomarker panels for early differential diagnoses of specific dementias and is a collaborative project between 7 European and 1 Australian centers.

Debby Tsuang, MD, MSc, is a professor at the University of Washington School of Medicine. She is also the Director of the GRECC Memory Disorder Clinic. Over the past 20 years, her research has focused on the genetics of schizophrenia and neurodegenerative disorders, particularly on the use of clinical phenotyping and innovative genomic technologies to elucidate the complex genetic architecture underlying schizophrenia and Alzheimer's disease (AD). She served as the Director of the Geriatric Research, Education, and Clinical Center (GRECC) at the VA Puget Sound Health (VAPS) from 2011-2022, in order to focus on her research on Alzheimer's Disease and related disorders. Her current research interests are two-pronged: 1) develop machine learning models in VA's vast electronic health records in order to assign ADRD probability scores in older Black and White Veterans; and 2) use mobile health devices to promote early diagnosis of dementia with Lewy bodies. In these capacities, she directs multidisciplinary efforts to better understand the biology, genetics, etiology, prevention, and treatment of these disorders, and she provide clinical expertise for the differential diagnosis of neurodegenerative disorders and treatment of behavioral disturbances in dementias.

Jennifer Weuve, ScD, MPH, is a Professor in the Department of Epidemiology of the Boston University School of Public Health (BUSPH). In her research, she pursues answers to questions in two major realms of human health: (1) the forces that contribute to the pathologic aging of the brain and body, and (2) the health effects of being exposed to environmental toxicants. Underlying all of her research is a foundation in epidemiologic methods. Dr. Weuve is PI or co-investigator of several projects that encompass both of these realms. For example, she is PI of the NIH-funded Air-Noise-Dementia Study (ANDS), which examines the hypothesis that long-term exposure to air pollution and noise from the community affect brain changes that we can see on MRI and, ultimately, the development of dementia. She is also MPI of AERONOSE, an investigation of olfactory pathways tying air pollution exposure to dementia risk that engages a multi-disciplinary team including neuropathologists, geochemists, and neurologists. Dr. Weuve has also contributed to efforts to understand the legacy of historic exposure to lead (Pb) on older adult cognition. These projects comprise a foundation for extending inquiries in numerous informative directions, such as the role of environmental injustice in producing dementia inequities. Dr. Weuve is a member of the editorial board of EPIDEMIOLOGY. She is also Co-Director of the international initiative, MEthods in LOngitudinal research on DEMentia (MELODEM) and PI of the NIH grant that supports it.

Kristine Yaffe, MD, attended Yale University for her undergraduate degree and the University of Pennsylvania for her medical degree. She then completed residencies in both Neurology and Psychiatry at the University of California, San Francisco. Dr. Yaffe is the Scola Endowed Chair

and Epstein Endowed Chair, Professor and Vice Chair of Psychiatry, Neurology, and Epidemiology, and Director of the Center for Population Brain Health at the University of California, San Francisco. In her research, clinical work, and mentoring, she has directed her efforts towards improving the care of patients with Alzheimers and other dementias. Dr. Yaffe is an internationally recognized expert in the epidemiology of dementia and cognitive aging. She serves as PI of almost a dozen NIH, Department of Defense, Veterans Administration, and foundation grants and is the foremost leader in identifying modifiable risk factors for dementia. Dr. Yaffe and her colleagues were the first to determine that potentially 30% of dementia risk is preventable. She pioneered early investigations on the roles of estrogen, physical activity, and cardiovascular factors in dementia risk, and more recently, her research group has led work on the connections between cognitive aging and traumatic brain injury, sleep disorders, and life course exposures. With over 700 peer-reviewed articles dedicated to improving population brain health (H-index=167), her work has formed the cornerstone for dementia prevention trials worldwide. In recognition of these groundbreaking accomplishments. Dr. Yaffe has received several prestigious honors including the American Academy of Neurology's Potamkin Prize for Alzheimer's Research in 2017, election to the National Academy of Medicine in 2019, the NIH Robert S. Gordon, Jr. Award in Epidemiology in 2021, and the Department of Veterans Affairs John B. Barnwell Award for Achievement in Clinical Research in 2022.